
Cerus Corporation has made significant strides in its business performance, driven by the success of its lead product, INTERCEPT Blood System. The company reported revenue growth of 22% in 2020, reaching $63.6 million.
This growth can be attributed to the increasing adoption of INTERCEPT by hospitals and blood banks worldwide. Cerus has established a strong presence in the global market, with a presence in over 30 countries.
The company's financial review highlights a net loss of $15.2 million in 2020, but this is largely due to ongoing investments in research and development. Despite this, Cerus remains committed to driving innovation in the field of blood safety.
Cerus has a strong cash position, with $94.4 million in cash and cash equivalents as of December 2020. This provides a solid foundation for future growth and development.
Suggestion: Intercept Pharmaceuticals
Financials
Cerus Corporation's financial health is a mixed bag. The company has a significant amount of debt relative to its equity, with a total debt/equity ratio of 176.07% as of the most recent quarter.
The company's cash flow situation is also a concern, with a levered free cash flow of only $4.17 million over the trailing 12 months. In contrast, the company's revenue over the same period was a more substantial $192.51 million.
Here are some key financial metrics for Cerus Corporation:
- Profit Margin: -9.81%
- Return on Assets (ROA): -3.66%
- Return on Equity (ROE): -35.56%
- Revenue (ttm): $192.51M
- Net Income Available to Common (ttm): -$18.88M
- Diluted EPS (ttm): -$0.1000
The company's market capitalization is $289.47 million, while its enterprise value is slightly higher at $310.34 million. The price-to-sales ratio is 1.47, and the price-to-book ratio is 5.22.
Take a look at this: Whirlpool Corp Share Price
Financial Statements
Financial statements are a crucial part of understanding a company's financial health. They provide a snapshot of a company's financial position at a specific point in time.
The balance sheet shows a company's assets, liabilities, and equity. In this case, the company has a total cash of $78.03M.
A company's debt-to-equity ratio is also an important metric, with a ratio of 176.07% indicating a high level of debt compared to equity.
Here's a breakdown of the company's cash flow:
The income statement shows a company's revenue and expenses over a specific period. In this case, the company has a revenue of $192.51M.
Take a look at this: Apple Gross Revenue
The company's profitability metrics are also concerning, with a profit margin of -9.81% and return on assets of -3.66%. This suggests that the company is struggling to generate profits.
The company's return on equity is also negative, at -35.56%, indicating that the company's equity is not generating returns.
The latest SEC filings provide valuable information about the company's activities. Here are some of the recent filings:
- SCHEDULE 13G/A filing on Aug 14, 2025
- S-8 filing on Aug 5, 2025
- 10-Q filing on Aug 5, 2025
- 8-K filing on Aug 5, 2025
- SCHEDULE 13G/A filing on Jul 30, 2025
- 8-K filing on Jun 23, 2025
- 8-K filing on Jun 9, 2025
- SD filing on May 30, 2025
- DEFA14A filing on May 23, 2025
- 10-Q filing on May 1, 2025
Valuation Measures
The valuation measures of a company can provide valuable insights into its financial health and potential for growth. Let's take a closer look at the numbers.
The market capitalization of the company is $289.47 million, a significant indicator of its overall value. This number is based on the total market value of outstanding shares.
Enterprise value, on the other hand, is $310.34 million, which includes the company's debt and cash. This measure gives a more comprehensive picture of the company's financial situation.
One important ratio to consider is the price-to-sales ratio, which is 1.47. This means that for every dollar of sales, the stock price is 1.47. This ratio can help us understand the company's profitability and value.
Another ratio to examine is the price-to-book ratio, which is 5.22. This means that the stock price is 5.22 times the book value of the company. This ratio can help us assess the company's financial health and potential for growth.
Here are the valuation measures in a concise table:
These numbers can help us make informed decisions about the company's financial situation and potential for growth.
Sales by Region
The United States was the largest market for Cerus Corporation in 2024, with sales reaching $111 million.
In 2021, the company's sales in the United States more than doubled from the previous year, reaching $67.5 million.
The company's sales in other countries also showed growth, reaching $49.5 million in 2024.
France was another significant market for Cerus Corporation, with sales reaching $19.69 million in 2024.
Belgium was a notable market for the company, with sales reaching $6.92 million in 2020.
Here's a breakdown of the company's sales by region:
Performance
Cerus Corporation's performance is a key aspect to consider when evaluating the company.
The trailing total returns as of 10/23/2025, which may include dividends or other distributions, provide a snapshot of the company's past performance.
We can compare this to the S&P 500 benchmark, which is a widely followed stock market index.
Performance Overview: Cers
As of October 23, 2025, the CERS has shown a strong trailing total return, which may include dividends or other distributions. This performance is a key indicator of the fund's success.
The benchmark for CERS is the S&P 500 (^GSPC), which provides a standard against which the fund's performance can be measured.
Why Is It Surging Today?
The concept of performance has been gaining momentum in recent years, and one reason for this surge is the increasing recognition of its impact on business success.
Research has shown that high-performing teams are 2.5 times more likely to outperform their competitors.

Companies are now placing a greater emphasis on performance metrics, such as productivity and efficiency.
According to a study, 80% of companies believe that performance metrics are essential for making informed business decisions.
As a result, employees are being held to higher standards, with 60% of companies using performance metrics to evaluate employee performance.
The focus on performance is also driving innovation, with 75% of companies investing in new technologies to improve performance.
Stock Information
Cerus Corporation is listed on the NASDAQ exchange under the ticker symbol CERS. This means you can easily find and track the company's stock performance.
The company's stock type is common stock, which is the most common type of stock and represents ownership in the company.
Cerus Corporation's fiscal year runs from January to December, which is a standard calendar year. This means the company's financial reports and results are typically released around the end of each year.
The company's reporting currency is USD, which is the United States dollar. This is the currency in which the company's financial reports and statements are presented.
Here's a summary of Cerus Corporation's stock information:
Market Analysis
Cerus Corporation is a biopharmaceutical company that has made significant advancements in the field of blood transfusion safety.
The company's flagship product, INTERCEPT Blood System, is a pathogen reduction technology that inactivates viruses, bacteria, and parasites in blood components, reducing the risk of transfusion-transmitted infections.
Cerus has established partnerships with major blood collection organizations and has received regulatory approvals in multiple countries.
The INTERCEPT Blood System has been used in over 100 million transfusions worldwide, demonstrating its effectiveness and safety.
Cerus Corporation has a strong financial foundation, with a market capitalization of over $1 billion and a revenue growth rate of 20% in the past year.
Related reading: Broadcasting Satellite System Corporation
Medical Devices
Cerus Corporation operates as a biomedical products company, focusing on developing and commercializing the INTERCEPT Blood System to enhance blood safety.
The company's INTERCEPT Blood System is a proprietary technology designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
Cerus Corporation offers INTERCEPT Blood Systems for platelets and plasma, red blood cells, and Cryoprecipitation.
Its plasma system produces pathogen-reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding.
The company sells platelet and plasma systems through its direct sales force and distributors in various regions, including the United States, Europe, and Latin America.
Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.
Earnings and Updates
Cerus Corporation has reported significant revenue growth in recent years. Their net sales have increased from $18.2 million in 2019 to $24.1 million in 2020.
The company's financial performance has been boosted by the growing demand for their Intercept Blood System, which is used to inactivate pathogens in plasma. This has led to increased sales and revenue for the company.
In 2020, Cerus Corporation reported a net loss of $10.2 million, but this was a significant improvement from the net loss of $15.5 million in 2019.
Readers also liked: Company That Merged with Sprint in 2020
Q2 Earnings Snapshot
Companies like Apple and Microsoft have reported their Q2 earnings, revealing some interesting facts. Apple's revenue reached $83.4 billion, a 2% increase from the same period last year.
You might enjoy: Apple Corporation Net Worth

The tech giant's net income was $20.6 billion, a 6% increase from Q2 2022. Apple's strong sales of iPhones and Macs contributed to the growth.
Microsoft's Q2 revenue came in at $56.5 billion, a 12% increase from the same period last year. The company's cloud computing business, Azure, saw a 31% increase in revenue.
Microsoft's net income was $16.5 billion, a 19% increase from Q2 2022. The company's strong performance in the cloud and productivity segments drove the growth.
Worth a look: Bose Corporation Revenue
Updates
As we dive into the updates, it's clear that there have been some significant changes. The company's revenue has seen a 25% increase in the past quarter, thanks in part to the successful launch of their new product.
This growth has been driven by a strong demand for their innovative technology, which has been adopted by over 500 businesses worldwide. The company's expansion into new markets has also played a key role in this success.

One of the biggest updates is the appointment of a new CEO, who brings a wealth of experience in the industry. This change is expected to bring fresh perspective and new ideas to the company.
The company's financials are looking strong, with a net income of $10 million in the last quarter. This is a significant increase from the previous quarter's net income of $5 million.
The company's stock price has also seen a significant boost, rising by 15% in the past month. This is likely due to the growing confidence in the company's future prospects.
The company is continuing to invest in research and development, with a focus on creating new and innovative products. This commitment to innovation is likely to drive further growth and success for the company.
Discover more: Income and Corporation Taxes Act 1988
Featured Images: pexels.com


